Intracoronary administration of tirofiban during percutaneous coronary intervention facilitates patients with acute coronary syndrome.

ABSTRACT: We assessed the efficacy and safety of tirofiban intracoronary versus intravenous administration during percutaneous coronary intervention for patients with acute coronary syndrome. The databases of PubMed, Web of Science, China National Knowledge Infrastructure, and WanFang Database were retrieved. A total of 437 articles were found, according to inclusive and exclusive criteria, 13 of which were finally included. Compared with subjects with intravenous administration, those with intracoronary administration were more likely to reach thrombolysis in myocardial infarction trial grade 3 flow (relative risk = 1.17, 95% confidence interval: 1.11-1.22), improve left ventricular ejection fraction (Standardized mean difference = 0.65, 95% confidence interval: 0.20-1.11). Intracoronary administra

SUBMITTER: Jia H 

PROVIDER: S-EPMC5739815 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature